Active substance
Dextran 40
- SFDA 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DEXTRAN 40 10% IN NORMAL SALINE | 10 % | Solution for infusion · Intravenous use | 1 Bag | SAR 23.70 | Generic · Prescription | KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| DEXTRAN 40 10% IN DEXTROSE | 10 % | Solution for infusion · Intravenous use | 1 Bottle | SAR 81.55 | NCE · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
| DEXTRAN 40 10% IN NORMAL SALINE | 10 % | Solution for infusion · Intravenous use | 1 Bottle | SAR 81.55 | NCE · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
| DEXTRAN 40 5% IN DEXTROSE | 5 % | Solution for infusion · Intravenous use | 1 Bottle | SAR 73.25 | NCE · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
| DEXTRAN 40 5% IN NORMAL SALINE | 5 % | Solution for infusion · Intravenous use | 1 Bottle | SAR 73.25 | NCE · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
Combinations containing Dextran 40
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.